Phenylethylamine: Possible Role in Depression and Antidepressive Drug Action

  • H. C. Sabelli
  • A. D. Mosnaim
  • A. J. Vazquez
Part of the Advances in Behavioral Biology book series (ABBI, volume 10)


The well-chosen title of this conference implies that emotional behavior can be coded in a simple alphabet consisting of a relatively small number of neuromodulators and synaptic transmitters0 One of the main difficulties in deciphering this code is that we know only a few of its “letters” [catecholamines (CA), serotonin (5HT), acetylcholine, etc,]. Toman and Sabelli (cf. Sabelli, 1964) proposed that not only is there a multiplicity of transmitters of various presynaptic origins, but there are also many endogenous chemicals that regulate neural function by modulating synaptic transmission mediated by other chemicals and by acting upon extrasynaptic membranes. 2-Phenylethyl amine (PEA) may represent one example of this concept of neuromodulators.


Brain Level Stimulant Action Biological Psychiatry Central Nervous System Effect Endogenous Depression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baldessarini, R.J., and Vogt, M., 1971, The uptake and subcellular distribution of aromatic amines in the brain of the rat, J. Neurochem. 18: 2519.PubMedCrossRefGoogle Scholar
  2. Biel, J.H., Nuhfer, P.A., Hoya, W.K., Leiser, H.A., and Abood, L.G., 1962, Cholinergic blockage as an approach to the development of new psychotropic agents, Ann. J. Y. Acad. Sei. 96: 251.CrossRefGoogle Scholar
  3. Boulton, A.A., and Milward, L., 1971, Separation, detection and quantitative analysis of urinary 3-phenyl ethylamine, Chrom. 57: 287.CrossRefGoogle Scholar
  4. Brunner, E.L., and Sabel1i, H.C., 1971, The effect of 5-hydroxy-indoleacetic acid on the action potential of the frog ventricle, Pharmacologist 13: 267.Google Scholar
  5. Carlsson, A., Fuxe, K., and Ungerstedt, U., 1968, The effect of imipramine on central 5-hydroxytryptami ne neurons, J. Pharm. Pharmacol. 20: 150.PubMedCrossRefGoogle Scholar
  6. Coppen, A., 1967, The biochemistry of affective disorders, Brit. Psychiat. 113: 1237.CrossRefGoogle Scholar
  7. Costa, E., and Neff, N.H., 1966, Isotopic and non-isotopic measure-ments of the rate of catecholamine biosynthesis, Jjn “Biochemistry and Pharmacology of the Basal Ganglia,” (E. Costa, L.J. Cote, and M.D. Tahr, eds.), pp. 141–156, Raven Press, New York.Google Scholar
  8. Creveling, C.R., Daly, J.W., Witkop, B., and Udenfriend, S., 1962, Substrates and inhibitors of dopamine-β-oxidase, Biochem. Biophys. Acta 64: 125.PubMedCrossRefGoogle Scholar
  9. Creveling, C.R., Daly, J.W., Tokuyama, T., and Witkop, B., 1968, The combined use of a-methyltyrosine and threo-dihydroxypheny1serine-selective reduction of dopamine levels in the central nervous system, Biochem. Pharmacology 17: 65.CrossRefGoogle Scholar
  10. Dewhurst, W.G., 1968, New theory of cerebral amine function and its clinical application, Nature 218: 1130.PubMedCrossRefGoogle Scholar
  11. Edwards, D.J., and Blau, K., 1972, Analysis of phenylethylamines in biological tissues by gas-liquid chromatography with electron-capture detection, Analyt. Biochem. 45: 387.PubMedCrossRefGoogle Scholar
  12. Edwards, D.J., and Blau, K., 1973, Phenylethylamines in brain and liver of rats with experimentally induced phenylketonuria-1ike characteristics, Biochem, J. 132: 95.Google Scholar
  13. Ehinger, B., and Myhrberg, H.E., 1971, Neijronal localization of dopamine, noradrenaline, and 5-hydroxytryptamine in the central and peripheral nervous system of Lumbricus terrestris (L.), Histochemie 28: 265.PubMedCrossRefGoogle Scholar
  14. Feldstein, A., Chang, G.H., and Kuchorki, J.M., 1970, Tryptophol, 5-hydroxytryptophol and 5-methoxytryptophol induced sleep in mice, Life Sciences 9: 323.PubMedCrossRefGoogle Scholar
  15. Fischer, E., Ludmer, R.I., and Sabelli, H.C., 1967, The antagonism of phenyl ethyl amine to catecholamines on mouse motor activity, Acta Physiol. Lat. Amer. 17: 15.PubMedGoogle Scholar
  16. Fischer, E., Heller, B., and Miro, A.N., 1968, β-Phenylethyl amine in human urine, Arzneim. Forsch. 18: 1486.Google Scholar
  17. Fischer, E., Spatz, H., Heller, B., and Reggiani, H., 1972a, Phenyl ethylamine content of human urine and rat brain, its alteration in pathological conditions and after drug administration, Experientia 28: 307.PubMedCrossRefGoogle Scholar
  18. Fischer, E., Spatz, H., Saavedra, J.M., Reggiani, H., Miro, A.H., and Heller, B., 1972b, Urinary elimination of phenyl ethyl amine, Biol. Psychiat. 5: 139.PubMedGoogle Scholar
  19. Fuxe, K., Grobecker, H., and Jonsson, J., 1967, The effect of β -phenyl ethyl amine on central and peripheral monoamine-containing neurons, Europ. J. Pharmacol. 2: 202.CrossRefGoogle Scholar
  20. Giardina, W.J., Sabel1i, H.C., and Aderman, M., 1970, Non-hydroxylated and deaminated derivatives of catecholamines on mouse exploratory behavior: A hypothesis of antidepressive action, Proc. 78th Ann. Conv. Amer, Psychol. Assoc., Miami Beach, Sept. 3–8, pp. 811–812.Google Scholar
  21. Giardina, W.J., Pedemonte, W.A., and Sabel1i, H.C., 1973, lontophoretic study of the effect of norepinephrine and 2-phenylethylamine on single cortical neurons, Life Science 12: 153.Google Scholar
  22. Goodwin, F.K., 1971, Psychiatric side effects of Levodopa in man, J.A.M.A. 218: 1915.PubMedCrossRefGoogle Scholar
  23. Goodwin, F.K., Murphy, D.L., Brodie, H.K.H., and Bunney, Jr., W.E., 1970, L-Dopa, catecholamines and behavior: a clinical and biochemical study in depressed patients, Biol. Psychiat. 2: 341.PubMedGoogle Scholar
  24. Grundfest, H., 1957, General problems of drug actions on bioelectrical phenomena, Ann. JN.Y. Acad. Sci. 66: 537.CrossRefGoogle Scholar
  25. Hartman, B.K., and Udenfriend, S., 1972, The application of immunological techniques to the study of enzymes regulating catecholamine synthesis and degradation, Pharmacol. Rev. 24: 311.PubMedGoogle Scholar
  26. Himwich, H.E., and Alpers, H.S., 1970, Psychophamiacology, in “Annual Reviews of Pharmacology,” vol. 10, (H.W. Elliot, W.C. Cutting, and R.H. Dreisback, eds.), PP. 313–334, Annual Reviews, Inc., Palo Alto, California.Google Scholar
  27. Holtz, P., 1966, Introductory remarks, Pharmacol. Review 18: 85.Google Scholar
  28. Inwang, E.E., Sugerman, J.H., De Martini, W.J., Mosnaim, A.D., and Sabel1i, H.C., 1972, Ultraviolet spectrophotometric determination of β-phenylethyl amine-like substances in biological samples and its possible correlation with depression, presented at the Annual Convention of the Society of Biological Psychiatry, Dallas, April 28–30, 1972.Google Scholar
  29. Inwang, E.E., Madabuike, U.P., and Mosnaim, A.D., 1973a, Evidence for the excretion of 2-phenylethyl amine glucuronide in human urine, Experientia (in press).Google Scholar
  30. Inwang, E.E., Mosnaim, A.D., and Sabel1i, U.C., 1973b, Isolation and characterization of phenylethylamine and phenylethanolamîne from human braîn, J. Neurochem. 20: 1469.PubMedCrossRefGoogle Scholar
  31. Jackson, D.M., and Temple, D.M., 1970, g-Phenylethyl ami ne as a cardiotonic constituent of tissue extracts, Comp. Gen, Pharmac. 1: 155.Google Scholar
  32. Jenkins, R.B., and Groh, R.H., 1970, Mental symptoms in Parkinsonian patients treated with L-DOPA, The Lancet 2: 177.CrossRefGoogle Scholar
  33. Jepson, J.B., Lovenberg, W., and Zaltzman, P., 1960, Amine metabolism studied in normal and Phenylketonurie humans by monoamine oxidase inhibition, Biochem. 74: 5.Google Scholar
  34. Kety, S., 1970, Brain amines and affective disorders, in “Brain Chemistry and Mental Disease,” (B.T. Ho, and W.M. McIsaac, eds.), pp. 237–244, Plenum Press, New York.Google Scholar
  35. Klaiber, E.L., Broverman, D.M., Vogel, W., Kobayashi, Y., and Moriarty, D., 1972, Effects of estrogen therapy on plasma MAO activity and EEG driving responses of depressed women, Amer. J. Psychiat. 128: 1492.PubMedGoogle Scholar
  36. Kopin, I.J., 1968, Identification of “true” and “false” transmitters in psychopharmacology, Public Health Service Publication 1836, ( D.H. Effron, ed. ), Washington, pp. 57–60.Google Scholar
  37. Loo, Y.H., 1967, Characterization of a new phenylalanine metabolite in phenylketonuria, J. Neurochem. 14: 813.CrossRefGoogle Scholar
  38. Maas, J.W., Fawcett, J., and Dekirmenjian, H., 1972, Catecholamine metabolism, depressive illness and drug response, Arch. Gen. Psychiat. 26: 252.PubMedCrossRefGoogle Scholar
  39. Mantegazza, P., and Riva, M., 1963, Amphetamine-1ike activity of g-phenylethyl amine, J. Pharm. 15: 472.CrossRefGoogle Scholar
  40. Marley, E., 1966, Behavioral and electrophysiological effects of catecholamines, Pharm. Rev. 18: 753.PubMedGoogle Scholar
  41. Molinoff, B.P., Landsberg, L., and Axel rod, J., 1969, An enzymatic assay for octopamine and other (S-hydroxylated phenyl ethyl amines, Pharmac. Exp. Ther. 170: 253.Google Scholar
  42. Mosnaim, A.D., and Inwang, E.E., 1973, A spectrophotometric method for the quantification of 2-phenylethyl amine in biological specimens, Anal. Biochem. (in press).Google Scholar
  43. Mosnaim, A.D., and Sabelli, H.C., 1971, Quantitative determination of the brain levels of a 3-phenylethyl amine-like substance in control and drug-treated mice, Pharmacoloqist 13: 283.Google Scholar
  44. Mosnaim, A.D., Inwang, E.E., and Sabel1i, H.C., 1972, Phenylethylamine-like substance(s) in mammalian brain and their increase by repeated electroshock seizures, presented at the Society for Neuroscience, Houston, October 8–11, 1972.Google Scholar
  45. Mosnaim, A.D., Inwang, E.E., Sugerman, J.H., De Martini, W.J., and Sabelli, H.C., 1973a, Ultraviolet spectrophotometric determination of 2-phenylethyl amine in biological samples and its possible correlation with depression, Biological Psychiatry 6 (3): 235.PubMedGoogle Scholar
  46. Mosnaim, A.D., Inwang, E.E., Sugerman, J.H., and Sabelli, H.C., 1973b, Identification of 2-phenylethyl amine in human urine by infrared and mass spectroscopy and its quantification in normal subjects and cardiovascular patients, Clinica Chimica Acta (in press).Google Scholar
  47. Mosnaim, A.D., Sabelli, H.C., and Inwang, E.E., 1973c, The influence of psychotropic drugs on the levels of endogenous 2-phenylethyl- amine in brain, presented at the Society of Biological Psychiatry, Montreal, June 8–10, 1973.Google Scholar
  48. Mosnaim, A.D., Whalley, C., Pedemonte, W.A., Vazquez, A.J., and Sabelli, H.C., 1973d, Further evidence for a role of 2-phenyl- ethylamine as a mediator for the stimulant action of β-tetra-hydrocannabinoi, to be presented at the Society for Neuroscience, San Diego, Nov. 1973.Google Scholar
  49. Nakajima, T., Kakimoto, Y., and Sano, I., 1964, Formation of phenyl-ethylamine in mammalian tissues and its effect on motor activity in the mouse, J. Pharm. 143: 319.Google Scholar
  50. Ng, L.K.Y., Lamprecht, F., Williams, R.B., and Kopin, I.J., 1973, A-Tetrahydrocannabinol and ethanol: differential effects on sympathetic activityin differing environmental setting, Seience 180: 1368.CrossRefGoogle Scholar
  51. Oates, J.A., Nirenberg, P.Z., Jepson, J.B., Sjverdrma, A., and Undenfriend, S., 1963, Conversion of phenylalanine to phenyl-ethylamine in patients with phenylketonuria, Proc. Soc. Exptl. Biol. and Med. 112: 1078.Google Scholar
  52. Pedemonte, W.A., and Sabel1i, H.C., 1973, Possible direct modulator role of serotonin and its metabolites on sleep mechanisms in newly- hatched chicks, to be presented at the Society for Neuroscienee, San Diego, Nov. 1973.Google Scholar
  53. Prange, Jr., H.J., 1973, The use of drugs in depression: its theoretical and practical basis, Psychiatric Annals 3: 56.Google Scholar
  54. Rodriguez Casanova, E., and Fernandez Labriola, R., 1972, Estudios sobrela Fenetilaminuri a en depresiones, Ann. Biol. Psychiat. 1: 5.Google Scholar
  55. Rothballer, A.B., 1959, The effects of catecholamines on the central nervous system, Pharmacol. Rev. 11: 494.PubMedGoogle Scholar
  56. Saavedra, J.M., and Axel rod, J., 1973, Demonstration and distribution of phenylethanolamine in brain and other tissues, Proc. Nat. Acad. Sci. (USA) 70: 769.CrossRefGoogle Scholar
  57. Sabelli, H.C., I960, Pressor effects of adrenergic agents and serotonin after the administration of imipramine, Arzneirn. — Forsch. 10: 935.Google Scholar
  58. Sabelli, H.C., 1964, A pharmacological strategy for the study of central modulator linkages, in “Recent Advances in Biological Psychiatry,” Vol. 6, (J, Wortis, ed.), pp. 145–182, Plenum Press, New York.Google Scholar
  59. Sabelli, H.C., 1970, Optic evoked potential changes induced by de-aminated metabolites of serotonin: 5-Hydroxytryptophol and 5-hydroxyindoleacetic acid, Experientia 26: 58.PubMedCrossRefGoogle Scholar
  60. Sabelli, H.C., and Giardina, W.J., 1970a, CNS effects of the alde-hyde products of brain monoamines, Biol. Psychiat. 2: 119.PubMedGoogle Scholar
  61. Sabelli, H.C., and Giardina, W.J., 1970b, Tryptaldehydes (Indole-acetaldehydes) in serotonergic sleep of newly hatched chicks, Arzneim. Forsch. 20: 74.Google Scholar
  62. Sabelli, H.C., and Giardina, W.J., 1971, The influence of inhibitors of amine metabolism on the effects of serotonin and its metabolites on the photic evoked potential in rabbits, Experientia 27: 64.PubMedCrossRefGoogle Scholar
  63. Sabelli, H.C., and Giardina, W.J., 1973a, Evidence for biological activity of deaminated metabolites of catecholamines, presented at the Society of Biological Psychiatry, Montreal, June 8–10.Google Scholar
  64. Sabelli, H.C., and Giardina, W.J., 1973b, Amine modulation of affective behavior, in “Chemical Modulation of Brain Function,” (H.C. Sabelli, ed.), pp. 225–259, Raven Press, New York.Google Scholar
  65. Sabelli, H.C., and Gorosito,M., 1969, Evidence for biogenic amine receptors in toad sciatic nerves, Int. J. Neuropharmacol. 8: 495.PubMedCrossRefGoogle Scholar
  66. Sabelli, H.C., and Mosnaim, A.D., 1973, Phenyl ethyl amine hypothesis of affective behavior, presented at the American Psychiatric Association, Honolulu, May 7–13, 1973.Google Scholar
  67. Sabelli, H.C., and Toman, J.E.P., 1961, Efectos electrocardiograficos de agentes antidepresivos, Rev. Soc. Argent. Biol. 37: 205.PubMedGoogle Scholar
  68. Sabel1iH.C., Levin, J.J., and Toman, J.E.P., 1961, Mecanismos colinergicos y agentes antidepresivos, Rev. Soc. Argent. Biol. 37: 87.PubMedGoogle Scholar
  69. Sabelli, H.C., Giardina, W.J., Alivisatos, S.G.A., Seth, P.K., and Ungar, F., 1969, Indoleacetaldehydes: Serotonin-like effects on the central nervous system, Nature (Lond.) 223: 73.CrossRefGoogle Scholar
  70. Sabelli, H.C., Giardina, W.J., and Alivisatos, S.G.A., 1970, Influ ence of serotonin and related substances upon photic evoked potentials of rabbit: Evidence for biological activity of the aldehyde derivative, Arzneim. Forsch. 20: 68.Google Scholar
  71. Sabelli, H.C., Giardina, W.J., andBartizal, F., 1971a, Photic evoked cortical potentials: Interaction of reserpine, monoamine oxidase inhibition and DOPA, Biol. Psychiat. 3: 273.PubMedGoogle Scholar
  72. Sabelli, H.C., Giardina, W.J., Mosnaim, A.D., and Sabelli, N.H., 1971b, A comparison of the functional roles of norepinephrine, dopamine and phenyl ethyl amine in the central nervous system, Proceedings of the Satellite Symposium “Central and Peripheral Adrenergic Systems” XXV International Congress of Physiological Sciences, Warsaw, August 3–6, 1971.Google Scholar
  73. Sabelli, H.C., Mosnaim, A.D., and Vazquez, A.J., 1973a, Possible role of 2-phenylethyl amine and L-DOPA in extrapyramidal disorders and their drug therapy, to be presented at the American Society for Pharmacology and Experimental Therapeutics, Michigan, August 19–23, 1973.Google Scholar
  74. Sabelli, H.C., Vazquez, A.J., and Flavin, D.F., 1973b, Differential effects of two putative neuromodulators: 2-phenylethyl amine and 2-phenylethanolamine, to be presented at the Society for Neuro-science, San Diego, Nov. 1973.Google Scholar
  75. Sabelli, H.C., Mosnaim, A.D., Vazquez, A.J., and Madrid-Pedemonte, L., 1973c, (-)-Trans-A9-tetrahydrocannabinoi-induced increase in brain 2-phenylethyl amine: its possible role in the psychological effect of marihuana, in “Drug Addiction: Behavioral Aspects,” (J. Singh, ed.), Futura Publishing Co., New York, in press.Google Scholar
  76. Sandler, M., and Youdim, M.B., 1972, Multiple forms of monoamine oxidase: functional significance, Pharmacol. Rev, 24: 331.PubMedGoogle Scholar
  77. Schildkraut, J.J., 1973, Norepinephrine metabolism in the patho-physiology and classification of depressive and manic disorders, in “Psychopathology and Psychopharmacology,” (J.O. Cole, A.Freed- man, and A. Friedhoff, eds.), John Hopkins Press, Baltimore, in press.Google Scholar
  78. Seeman, P., 1972, The membrane actions of anesthetics and tranquilizers, Pharmacol. Rev. 24: 583.PubMedGoogle Scholar
  79. Sulser, F., and Sanders-Bush, E., 1971, Effect of drugs on amines in the CNS, Ann Rev. Pharmacol. 11: 209.PubMedCrossRefGoogle Scholar
  80. Toman, J.E.P., and Sabel1i, H.C., 1968, Neuropharmacology of earthworm giant fibers, Int. Neuropharmacol. 7: 543.CrossRefGoogle Scholar
  81. Vane, J.B., 1960, The actions of sympathomimetic amines on tryptamine receptors, in “Adrenergic Mechanisms (A CIBA Foundation Symposium)” (J.R. Vane, G.E. Wolstenholme, and M. O’Connor, eds.), pp. 356–372, J. and A. Churchill, Ltd., London.Google Scholar
  82. Vazquez, A.J., and Krip, G., 1973, Interactions between amphetamine and serotonergic agents on cat’s isolated cerebral cortex, Biol. Psychiatry 7: 11.PubMedGoogle Scholar
  83. Vazquez, A.J., Giardina, W.J., Madrid-Pedemonte, L., Mosnaim, A.D., and Sabelli, H.C., 1973, Direct role of DOPA in the central nervous system, to be presented at the Society for Neurosei enee, San Diego, Nov. 1973.Google Scholar
  84. Whalley, C., Mosnaim, A.D., and Sabel1i, H.C., 1973, 2-Phenylethylamine in rabbit brain and liver: its synthesis, metabolism and role in the action of imipramine, pargyline, and marihuana, to be presented at the American Society for Pharmacology and Experimental Therapeutics, Michigan, August 19–23, 1973.Google Scholar
  85. Yang, H-YT., and Neff, N.H., 1973, Monoamine oxidase: I. a natural substrate for type B enzyme, Fed. Proc. 32: 797.Google Scholar

Copyright information

© Plenum Press, New York 1974

Authors and Affiliations

  • H. C. Sabelli
    • 1
  • A. D. Mosnaim
    • 1
  • A. J. Vazquez
    • 1
  1. 1.University of Health Sciences/The Chicago Medical SchoolChicagoUSA

Personalised recommendations